News
DGAP-News: Abivax postpones its Annual General Meeting to June 19, 2020
DGAP-News: Abivax postpones its Annual General Meeting to June 19, 2020
DGAP-News: Abivax verschiebt seine ordentliche Hauptversammlung auf den 19. Juni 2020
DGAP-News: Abivax verschiebt seine ordentliche Hauptversammlung auf den 19. Juni 2020
DGAP-News: ABIVAX: €36 millionen nicht-verwässernde Finanzierung von Bpifrance für Abivax' ABX464 Covid-19-Programm
DGAP-News: ABIVAX: €36 millionen nicht-verwässernde Finanzierung von Bpifrance für Abivax' ABX464 Covid-19-Programm
DGAP-News: ABIVAX: €36 million non-dilutive funding from Bpifrance for Abivax' ABX464 Covid-19 program
DGAP-News: ABIVAX: €36 million non-dilutive funding from Bpifrance for Abivax' ABX464 Covid-19 program
Pharnext Presents a Business Update Webcast on May 20th, 2020
Pharnext Presents a Business Update Webcast on May 20th, 2020
DGAP-News: ABX464 hemmt die Replikation von SARS-CoV-2 (COVID-19) im rekonstituierten humanen Atemwegsepithelmodell
DGAP-News: ABX464 hemmt die Replikation von SARS-CoV-2 (COVID-19) im rekonstituierten humanen Atemwegsepithelmodell
DGAP-News: ABX464 inhibits replication of SARS-CoV-2 (COVID-19) in reconstituted human respiratory epithelium model
DGAP-News: ABX464 inhibits replication of SARS-CoV-2 (COVID-19) in reconstituted human respiratory epithelium model
DGAP-News: Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized Phase 2b/3 clinical trial
DGAP-News: Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized Phase 2b/3 clinical trial
DGAP-News: Abivax erhält Genehmigung der ANSM und der Ethikkommission zur Testung seines Entwicklungskandidaten ABX464 in einer randomisierten Phase-2b/3-Studie mit 1.034 Covid-19-Patienten
DGAP-News: Abivax erhält Genehmigung der ANSM und der Ethikkommission zur Testung seines Entwicklungskandidaten ABX464 in einer randomisierten Phase-2b/3-Studie mit 1.034 Covid-19-Patienten
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
DGAP-News: Abivax verschiebt Veröffentlichung des Referenzdokuments ('Universal Registration Document', URD)
DGAP-News: Abivax verschiebt Veröffentlichung des Referenzdokuments ('Universal Registration Document', URD)
DGAP-News: Abivax postpones the publication of the yearly universal registration document ('URD')
DGAP-News: Abivax postpones the publication of the yearly universal registration document ('URD')
Pharnext Reports Financial Results for Year-End 2019
Pharnext Reports Financial Results for Year-End 2019
Pharnext and the University Hospital Institute Méditerranée Infection Announce a Joint Effort to Evaluate Repurposed Drugs for Potential Use Against the COVID-19 Virus
Pharnext and the University Hospital Institute Méditerranée Infection Announce a Joint Effort to Evaluate Repurposed Drugs for Potential Use Against the COVID-19 Virus
Pharnext Announces the Appointment of David Horn Solomon as Chief Executive Officer
Pharnext Announces the Appointment of David Horn Solomon as Chief Executive Officer
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Pharnext Announces Identification of a Large Set of Frequently Prescribed Drugs to be Repurposed for Fighting COVID-19, Using its PleotherapyTM Platform
Pharnext Announces Identification of a Large Set of Frequently Prescribed Drugs to be Repurposed for Fighting COVID-19, Using its PleotherapyTM Platform
Pharnext Announces PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A has Been Granted Promising Innovative Medicine (PIM) Designation by UK Medicines and Healthcare Products Regulatory Agency
Pharnext Announces PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A has Been Granted Promising Innovative Medicine (PIM) Designation by UK Medicines and Healthcare Products Regulatory Agency
DGAP-News: Abivax veröffentlicht Finanzergebnisse für das Jahr 2019 und gibt Update zur Unternehmensentwicklung
DGAP-News: Abivax veröffentlicht Finanzergebnisse für das Jahr 2019 und gibt Update zur Unternehmensentwicklung
DGAP-News: Abivax 2019 Financial Results and Operations Update
DGAP-News: Abivax 2019 Financial Results and Operations Update
DGAP-News: Abivax 2020 Financial Communication Calendar
DGAP-News: Abivax 2020 Financial Communication Calendar
Pharnext raises € 7.7 million in a private placement
Pharnext raises € 7.7 million in a private placement
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
DGAP-News: Abivax schließt ersten Patienten in US-amerikanische klinische Phase-1/2-Studie mit ABX196 zur Behandlung des Leberzellkarzinoms ein
DGAP-News: Abivax schließt ersten Patienten in US-amerikanische klinische Phase-1/2-Studie mit ABX196 zur Behandlung des Leberzellkarzinoms ein